The company reported second-quarter revenue Wednesday that included $248.4 million of back royalties and associated interest related to the successful outcome of an arbitration case with J&J’s Janssen.
Amid the impending drug pricing pressures from the Inflation Reduction Act, Roche is discontinuing a mid-stage hemophilia A gene therapy candidate and four other early-stage hopefuls.
The results are based, on average, across two late-stage studies after intensive lifestyle changes or with continued treatment, before patients stopped taking the drug.
The company now expects revenue from core business to grow in the range of 11.3%-12.6% for the year, compared with 9.5%-11% estimated earlier.
Today BMS said its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
The factory that fills the self-injection pens for booming weight-loss drug Wegovy has repeatedly breached U.S. sterile-safety rules in recent years and staff have failed to perform required quality checks, according to a Reuters review of regulatory documents.
AWS HealthScribe is a new HIPAA-eligible service that empowers healthcare software providers to build clinical applications that use speech recognition and generative AI to save clinicians time by generating clinical documentation.
Oncologists are deeply concerned about the limited alternatives to two critical chemotherapy drugs, which are not as effective in treating certain types of cancer and can even be more toxic. This scarcity of backup therapies poses particularly troubling prospects for patients with ovarian, testicular, breast, lung and head and neck cancers.
While GlaxoSmithKline is anticipating a slower uptake of respiratory syncytial virus vaccine Arexvy, CEO Emma Walmsley said Wednesday the company is pinning much of its growth on the vaccine’s performance.
Global recruitment for the trial has begun, with the first patients being enrolled in Australia, the companies said, adding that the study would take place in more than 25 countries around the world.